ICU Medical Receives Moderate Buy Rating Amid Analyst Activity

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have garnered a consensus recommendation of “Moderate Buy” from six research firms currently covering the company, according to data from MarketBeat.com. This analysis reflects the diverse opinions among analysts, with one rating the stock as a sell, one as hold, three as buy, and one as strong buy.

The average twelve-month price target for ICU Medical among these analysts is set at $181.75. The stock has been the subject of various evaluations, with notable reports issued by several firms. For instance, Weiss Ratings reaffirmed a “sell (d-)” rating on October 8, while Raymond James Financial reduced its price target from $187.00 to $180.00, maintaining a “strong buy” recommendation on August 8. Similarly, Piper Sandler raised its price objective from $153.00 to $172.00 and rated the company as “overweight” on November 7. Contrastingly, Wall Street Zen downgraded its rating from buy to hold on November 15.

Recent Earnings Performance

ICU Medical’s most recent earnings announcement occurred on November 6, when the company reported earnings of $2.03 per share for the quarter, surpassing the consensus estimate of $1.43 by $0.60. The company reported revenues of $533.30 million, exceeding expectations of $511.46 million. However, the revenue marked an 8.9% decline compared to the same quarter the previous year. Despite the dip, ICU Medical set its fiscal year 2025 guidance between $7.350 and $7.650 EPS, with analysts anticipating earnings per share of $4.11 for the current year.

Insider Transactions and Institutional Holdings

In related news, Vice President Virginia Ruth Sanzone sold 930 shares of ICU Medical on November 11 at an average price of $142.34, amounting to approximately $132,376.20. Following this transaction, Sanzone retains 5,456 shares in the company, valued at around $776,607.04. This sale represents a 14.56% reduction in her ownership.

Additionally, Director Elisha W. Finney sold 1,285 shares on the same day at an average price of $140.42, totaling about $180,439.70. After this sale, Finney holds 3,995 shares, valued at approximately $560,977.90, reflecting a 24.34% decrease in his stake.

Institutional investors control a significant portion of ICU Medical’s stock, with approximately 96.10% owned by institutional investors and hedge funds. Recent activity includes new stakes acquired by EP Wealth Advisors LLC worth about $479,000 and Vident Advisory LLC, which invested around $270,000. Woodline Partners LP increased its stake by 31.6% in the first quarter, now owning 160,910 shares valued at approximately $22.34 million.

About ICU Medical

ICU Medical, Inc. designs and manufactures medical devices primarily used in infusion therapy, vascular access, and vital care applications globally. Its product range includes needle-free options such as the MicroClave and ChemoClave, as well as various devices aimed at improving safety and efficacy in medical treatments.

As ICU Medical continues to navigate market conditions, analysts will be closely monitoring the company’s performance and strategic decisions in the coming months.